A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

NCT06963398 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: HS-10529

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.